Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 121-125, 2005.
Article
em Zh
| WPRIM
| ID: wpr-353234
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To explore the inhibitory effect of combination of lamivudine with thymosin alpha1 (Talpha1) on the replication of duck hepatitis B virus (DHBV).</p><p><b>METHODS</b>Peking ducks of 1 d old were challenged with DHBV-positive serum and used as a duck hepatitis B model. After treated with lamivudine for three months, the ducks were randomly grouped and treated with or without Talpha1 for 8 d. Serum DHBV titrate was observed by semi-quantitative PCR, and inflammation and degeneration of hepatocytes were observed by pathology examination.</p><p><b>RESULTS</b>The serum DHBV titrate was significantly reduced (4483.2+/-5193.4 compared with 9351.8+/-5059.6) after lamivudine treatment, and it was reduced more significantly(1692.2+/-589.2) after combination treatment with Talpha1. Lamivudine reduced the degeneration degree of hepatocytes (3.2+/-0.8 compared with 4.6+/-0.5) and the inflammation degree of liver (6.2+/-3.3 compared with 8.6+/-2.8). The combination treatment with Talpha1 increased liver inflammation degree (9.0+/-5.2).</p><p><b>CONCLUSION</b>Both Talpha1 and lamivudine may reduce the replication of DHBV in Peking ducks and combination treatment may have the better anti-virus effect and enhance immune response in liver.</p>
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Antivirais
/
Timosina
/
Virologia
/
Replicação Viral
/
Vírus da Hepatite B do Pato
/
Células Cultivadas
/
Infecções por Hepadnaviridae
/
Lamivudina
/
Hepatócitos
/
Usos Terapêuticos
Limite:
Animals
Idioma:
Zh
Revista:
Journal of Zhejiang University. Medical sciences
Ano de publicação:
2005
Tipo de documento:
Article